Melanoma Clinical Practice Guidelines in OncologyNCCN Categories of Evidence and ConsensusCategory 1: The recommendation is based on high-level evidence (e.g., randomized controlled trials) and there is uniform NCCN consensus.Category 2A: The recommendation is based on lower-level evidence and there is uniform NCCN consensus.Category 2B: The recommendation is based on lower-level evidence and there is nonuniform NCCN consensus (but no major disagreement).Category 3: The recommendation is based on any level of evidence but reflects major disagreement.All recommendations are category 2A unless otherwise noted.Clinical trials: The NCCN believes that the best management for any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.In 2008, an estimated 62,480 new cases of melanoma will have been diagnosed and approximately 8420 patients will have died of the disease in the United States.1 However, these projections for new cases may represent a substantial underestimation, because many superficial and in situ melanomas treated in the outpatient setting are not reported. The incidence of melanoma continues to increase dramatically. Melanoma is increasing in men more rapidly than any other malignancy and more rapidly in women than any other malignancy except lung cancer. For someone born in the United States in 2005, the lifetime risk for developing melanoma may be as high as 1 in 55.2 Melanoma ranks second to adult leukemia in terms of loss of years of potential life, per death. The median age at diagnosis is 59 years.Risk factors for melanoma include...

If the inline PDF is not rendering correctly, you can download the PDF file here.

References

  • 1

    JemalASiegelRWardE. Cancer statistics, 2008. CA Cancer J Clin2008;58:7196.

  • 2

    Surveillance Epidemiology and End Results. SEER stats fact sheet. Available at: http://seer.cancer.gov/statfacts/html/melan. html#ref11. Accessed 8 December 2008.

    • Search Google Scholar
    • Export Citation
  • 3

    NaeyaertJMBrochezL. Clinical practice. Dysplastic nevi. N Engl J Med2003;349:22332240.

  • 4

    RigelDSRiversJKKopfAW. Dysplastic nevi. Markers for increased risk for melanoma. Cancer1989;63:386389.

  • 5

    IvryGBOgleCAShimEK. Role of sun exposure in melanoma. Dermatol Surg2006;32:481492.

  • 6

    JensenEHMargolinKASondakVK. Melanoma and other skin cancers. In: PazdurRCoiaLHoskinsWJWagmanLD eds. Cancer Management: A Multidisciplinary Approach9th edition. New York: CMP Media; 2005:531562.

    • Search Google Scholar
    • Export Citation
  • 7

    TsaoHAtkinsMBSoberAJ. Management of cutaneous melanoma. N Engl J Med2004;351:9981012.

  • 8

    BalchCMBuzaidACSoongSJ. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol2001;19:36353648.

    • Search Google Scholar
    • Export Citation
  • 9

    GreeneFLPageDLFlemingID. AJCC Cancer Staging Manual6th ed. New York: Springer-Verlag; 2002.

  • 10

    BalchCMSoongSJGershenwaldJE. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol2001;19:36223634.

    • Search Google Scholar
    • Export Citation
  • 11

    BarnhillRLKatzenJSpatzA. The importance of mitotic rate as a prognostic factor for localized cutaneous melanoma. J Cutan Pathol2005;32:268273.

    • Search Google Scholar
    • Export Citation
  • 12

    AzzolaMFShawHMThompsonJF. Tumor mitotic rate is a more powerful prognostic indicator than ulceration in patients with primary cutaneous melanoma: an analysis of 3661 patients from a single center. Cancer2003;97:14881498.

    • Search Google Scholar
    • Export Citation
  • 13

    FranckenABShawHMThompsonJF. The prognostic importance of tumor mitotic rate confirmed in 1317 patients with primary cutaneous melanoma and long follow-up. Ann Surg Oncol2004;11:426433.

    • Search Google Scholar
    • Export Citation
  • 14

    GimottyPAElderDEFrakerDL. Identification of high-risk patients among those diagnosed with thin cutaneous melanomas. J Clin Oncol2007;25:11291134.

    • Search Google Scholar
    • Export Citation
  • 15

    PaekSCGriffithKAJohnsonTM. The impact of factors beyond Breslow depth on predicting sentinel lymph node positivity in melanoma. Cancer2007;109:100108.

    • Search Google Scholar
    • Export Citation
  • 16

    SondakVKTaylorJMSabelMS. Mitotic rate and younger age are predictors of sentinel lymph node positivity: lessons learned from the generation of a probabilistic model. Ann Surg Oncol2004;11:247258.

    • Search Google Scholar
    • Export Citation
  • 17

    SoberAJChuangTYDuvicM. Guidelines of care for primary cutaneous melanoma. J Am Acad Dermatol2001;45:579586.

  • 18

    NeumanHBPatelAIshillN. A single-institution validation of the AJCC staging system for stage IV melanoma. Ann Surg Oncol2008;15:20342041.

    • Search Google Scholar
    • Export Citation
  • 19

    CascinelliNBelliFSantinamiM. Sentinel lymph node biopsy in cutaneous melanoma: the WHO Melanoma Program experience. Ann Surg Oncol2000;7:469474.

    • Search Google Scholar
    • Export Citation
  • 20

    BuzaidACSandlerABManiS. Role of computed tomography in the staging of primary melanoma. J Clin Oncol1993;11:638643.

  • 21

    WangTSJohnsonTMCascadePN. Evaluation of staging chest radiographs and serum lactate dehydrogenase for localized melanoma. J Am Acad Dermatol2004;51:399405.

    • Search Google Scholar
    • Export Citation
  • 22

    YancovitzMFineltNWarychaMA. Role of radiologic imaging at the time of initial diagnosis of stage T1b-T3b melanoma. Cancer2007;110:11071114.

    • Search Google Scholar
    • Export Citation
  • 23

    AloiaTAGershenwaldJEAndtbackaRH. Utility of computed tomography and magnetic resonance imaging staging before completion lymphadenectomy in patients with sentinel lymph node-positive melanoma. J Clin Oncol2006;24:28582865.

    • Search Google Scholar
    • Export Citation
  • 24

    GoldJSJaquesDPBusamKJ. Yield and predictors of radiologic studies for identifying distant metastases in melanoma patients with a positive sentinel lymph node biopsy. Ann Surg Oncol2007;14:21332140.

    • Search Google Scholar
    • Export Citation
  • 25

    MirandaEPGertnerMWallJ. Routine imaging of asymptomatic melanoma patients with metastasis to sentinel lymph nodes rarely identifies systemic disease. Arch Surg2004;139:831836; discussion 836–837.

    • Search Google Scholar
    • Export Citation
  • 26

    BuzaidACTinocoLRossMI. Role of computed tomography in the staging of patients with local-regional metastases of melanoma. J Clin Oncol1995;13:21042108.

    • Search Google Scholar
    • Export Citation
  • 27

    JohnsonTMFaderDJChangAE. Computed tomography in staging of patients with melanoma metastatic to the regional nodes. Ann Surg Oncol1997;4:396402.

    • Search Google Scholar
    • Export Citation
  • 28

    KuvshinoffBWKurtzCCoitDG. Computed tomography in evaluation of patients with stage III melanoma. Ann Surg Oncol1997;4:252258.

  • 29

    ClarkPBSooVKraasJ. Futility of fluorodeoxyglucose F 18 positron emission tomography in initial evaluation of patients with T2 to T4 melanoma. Arch Surg2006;141:284288.

    • Search Google Scholar
    • Export Citation
  • 30

    MaubecELumbrosoJMassonF. F-18 fluorodeoxy-D-glucose positron emission tomography scan in the initial evaluation of patients with a primary melanoma thicker than 4 mm. Melanoma Res2007;17:147154.

    • Search Google Scholar
    • Export Citation
  • 31

    WagnerJDSchauweckerDDavidsonD. Inefficacy of F-18 fluorodeoxy-D-glucose-positron emission tomography scans for initial evaluation in early-stage cutaneous melanoma. Cancer2005;104:570579.

    • Search Google Scholar
    • Export Citation
  • 32

    BradyMSAkhurstTSpanknebelK. Utility of preoperative [(18)]f fluorodeoxyglucose-positron emission tomography scanning in high-risk melanoma patients. Ann Surg Oncol2006;13:525532.

    • Search Google Scholar
    • Export Citation
  • 33

    National Institutes of Health. After treatment of early melanoma, should patients and family members be followed? Why and How?NIH Consensus Statement1992;10:126.

    • Search Google Scholar
    • Export Citation
  • 34

    VeronesiUCascinelliN. Narrow excision (1-cm margin). A safe procedure for thin cutaneous melanoma. Arch Surg1991;126:438441.

  • 35

    VeronesiUCascinelliNAdamusJ. Thin stage I primary cutaneous malignant melanoma. Comparison of excision with margins of 1 or 3 cm. N Engl J Med1988;318:11591162.

    • Search Google Scholar
    • Export Citation
  • 36

    BalchCMSoongSJSmithT. Long-term results of a prospective surgical trial comparing 2 cm vs. 4 cm excision margins for 740 patients with 1-4 mm melanomas. Ann Surg Oncol2001;8:101108.

    • Search Google Scholar
    • Export Citation
  • 37

    BalchCMUristMMKarakousisCP. Efficacy of 2-cm surgical margins for intermediate-thickness melanomas (1 to 4 mm). Results of a multi-institutional randomized surgical trial. Ann Surg1993;218:262267; discussion 267–269.

    • Search Google Scholar
    • Export Citation
  • 38

    Cohn-CedermarkGRutqvistLEAnderssonR. Long term results of a randomized study by the Swedish Melanoma Study Group on 2-cm versus 5-cm resection margins for patients with cutaneous melanoma with a tumor thickness of 0.8-2.0 mm. Cancer2000;89:14951501.

    • Search Google Scholar
    • Export Citation
  • 39

    KhayatDRixeOMartinG. Surgical margins in cutaneous melanoma (2 cm versus 5 cm for lesions measuring less than 2.1-mm thick). Cancer2003;97:19411946.

    • Search Google Scholar
    • Export Citation
  • 40

    ThomasJMNewton-BishopJA’HernR. Excision margins in high-risk malignant melanoma. N Engl J Med2004;350:757766.

  • 41

    HaighPIDiFronzoLAMcCreadyDR. Optimal excision margins for primary cutaneous melanoma: a systematic review and meta-analysis. Can J Surg2003;46:419426.

    • Search Google Scholar
    • Export Citation
  • 42

    JohnsonTMHeadingtonJTBakerSRLoweL. Usefulness of the staged excision for lentigo maligna and lentigo maligna melanoma: the ”square” procedure. J Am Acad Dermatol1997;37:758764.

    • Search Google Scholar
    • Export Citation
  • 43

    ZitelliJABrownCHanusaBH. Mohs micrographic surgery for the treatment of primary cutaneous melanoma. J Am Acad Dermatol1997;37:236245.

    • Search Google Scholar
    • Export Citation
  • 44

    CotterMAMcKennaJKBowenGM. Treatment of lentigo maligna with imiquimod before staged excision. Dermatol Surg2008;34:147151.

  • 45

    NaylorMFCrowsonNKuwaharaR. Treatment of lentigo maligna with topical imiquimod. Br J Dermatol2003;149(Suppl 66):6670.

  • 46

    PowellAMRussell-JonesRBarlowRJ. Topical imiquimod immunotherapy in the management of lentigo maligna. Clin Exp Dermatol2004;29:1521.

    • Search Google Scholar
    • Export Citation
  • 47

    SpennyMLWalfordJWerchniakAE. Lentigo maligna (melanoma in situ) treated with imiquimod cream 5%: 12 case reports. Cutis2007;79:149152.

    • Search Google Scholar
    • Export Citation
  • 48

    JohnsonTMSondakVKBichakjianCKSabelMS. The role of sentinel lymph node biopsy for melanoma: evidence assessment. J Am Acad Dermatol2006;54:1927.

    • Search Google Scholar
    • Export Citation
  • 49

    MortonDLCochranAJThompsonJF. Sentinel node biopsy for early-stage melanoma: accuracy and morbidity in MSLT-I, an international multicenter trial. Ann Surg2005;242:302311; discussion 311–303.

    • Search Google Scholar
    • Export Citation
  • 50

    MortonDLThompsonJFCochranAJ. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med2006;355:13071317.

  • 51

    ThompsonJFShawHM. Sentinel node mapping for melanoma: results of trials and current applications. Surg Oncol Clin N Am2007;16:3554.

  • 52

    WrightBEScheriRPYeX. Importance of sentinel lymph node biopsy in patients with thin melanoma. Arch Surg2008;143:892899; discussion 899–900.

    • Search Google Scholar
    • Export Citation
  • 53

    BleicherRJEssnerRFoshagLJ. Role of sentinel lymphadenectomy in thin invasive cutaneous melanomas. J Clin Oncol2003;21:13261331.

  • 54

    RanieriJMWagnerJDWenckS. The prognostic importance of sentinel lymph node biopsy in thin melanoma. Ann Surg Oncol2006;13:927932.

  • 55

    WongSLBradyMSBusamKJCoitDG. Results of sentinel lymph node biopsy in patients with thin melanoma. Ann Surg Oncol2006;13:302309.

  • 56

    FerroneCRPanageasKSBusamK. Multivariate prognostic model for patients with thick cutaneous melanoma: importance of sentinel lymph node status. Ann Surg Oncol2002;9:637645.

    • Search Google Scholar
    • Export Citation
  • 57

    GershenwaldJEMansfieldPFLeeJERossMI. Role for lymphatic mapping and sentinel lymph node biopsy in patients with thick (> or = 4 mm) primary melanoma. Ann Surg Oncol2000;7:160165.

    • Search Google Scholar
    • Export Citation
  • 58

    GutzmerRSatzgerIThomsKM. Sentinel lymph node status is the most important prognostic factor for thick (> or = 4 mm) melanomas. J Dtsch Dermatol Ges2008;6:198203.

    • Search Google Scholar
    • Export Citation
  • 59

    EdwardsMJMartinKDMcMastersKM. Lymphatic mapping and sentinel lymph node biopsy in the staging of melanoma. Surg Oncol1998;7:5157.

  • 60

    GlassFLCottamJAReintgenDSFenskeNA. Lymphatic mapping and sentinel node biopsy in the management of high-risk melanoma. J Am Acad Dermatol1998;39:603610.

    • Search Google Scholar
    • Export Citation
  • 61

    KangJCWanekLAEssnerR. Sentinel lymphadenectomy does not increase the incidence of in-transit metastases in primary melanoma. J Clin Oncol2005;23:47644770.

    • Search Google Scholar
    • Export Citation
  • 62

    MortonDLThompsonJFEssnerR. Validation of the accuracy of intraoperative lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: a multicenter trial. Multicenter Selective Lymphadenectomy Trial Group. Ann Surg1999;230:453463; discussion 463–465.

    • Search Google Scholar
    • Export Citation
  • 63

    FontaineDParkhillWGreerWWalshN. Partial regression of primary cutaneous melanoma: is there an association with subclinical sentinel lymph node metastasis?Am J Dermatopathol2003;25:371376.

    • Search Google Scholar
    • Export Citation
  • 64

    MorrisKTBusamKJBeroS. Primary cutaneous melanoma with regression does not require a lower threshold for sentinel lymph node biopsy. Ann Surg Oncol2008;15:316322.

    • Search Google Scholar
    • Export Citation
  • 65

    CoitDG. Extent of groin dissection for melanoma. Surg Clin North Am1992;1:271280.

  • 66

    CoitDGBrennanMF. Extent of lymph node dissection in melanoma of the trunk or lower extremity. Arch Surg1989;124:162166.

  • 67

    ShenPConfortiAMEssnerR. Is the node of Cloquet the sentinel node for the iliac/obturator node group?Cancer J2000;6:9397.

  • 68

    CascinelliNBombardieriEBufalinoR. Sentinel and nonsentinel node status in stage IB and II melanoma patients: two-step prognostic indicators of survival. J Clin Oncol2006;24:44644471.

    • Search Google Scholar
    • Export Citation
  • 69

    LeeJHEssnerRTorisu-ItakuraH. Factors predictive of tumor-positive nonsentinel lymph nodes after tumor-positive sentinel lymph node dissection for melanoma. J Clin Oncol2004;22:36773684.

    • Search Google Scholar
    • Export Citation
  • 70

    CascinelliNBelliFMacKieRM. Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: a randomised trial. Lancet2001;358:866869.

    • Search Google Scholar
    • Export Citation
  • 71

    GrobJJDrenoBde la SalmoniereP. Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma. Lancet1998;351:19051910.

    • Search Google Scholar
    • Export Citation
  • 72

    PehambergerHSoyerHPSteinerA. Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group. J Clin Oncol1998;16:14251429.

    • Search Google Scholar
    • Export Citation
  • 73

    HancockBWWheatleyKHarrisS. Adjuvant interferon in high-risk melanoma: the AIM HIGH Study--United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon alfa-2a in high-risk resected malignant melanoma. J Clin Oncol2004;22:5361.

    • Search Google Scholar
    • Export Citation
  • 74

    EggermontAMSuciuSMacKieR. Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial. Lancet2005;366:11891196.

    • Search Google Scholar
    • Export Citation
  • 75

    KirkwoodJMStrawdermanMHErnstoffMS. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group trial EST 1684. J Clin Oncol1996;14:717.

    • Search Google Scholar
    • Export Citation
  • 76

    KirkwoodJMIbrahimJGSondakVK. High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol2000;18:24442458.

    • Search Google Scholar
    • Export Citation
  • 77

    KirkwoodJMIbrahimJGSosmanJA. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol2001;19:23702380.

    • Search Google Scholar
    • Export Citation
  • 78

    GogasHIoannovichJDafniU. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med2006;354:709718.

    • Search Google Scholar
    • Export Citation
  • 79

    LensMBDawesM. Interferon alfa therapy for malignant melanoma: a systematic review of randomized controlled trials. J Clin Oncol2002;20:18181825.

    • Search Google Scholar
    • Export Citation
  • 80

    KirkwoodJMManolaJIbrahimJ. A pooled analysis of Eastern Cooperative Oncology Group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res2004;10:16701677.

    • Search Google Scholar
    • Export Citation
  • 81

    VermaSQuirtIMcCreadyD. Systematic review of systemic adjuvant therapy for patients at high risk for recurrent melanoma. Cancer2006;106:14311442.

    • Search Google Scholar
    • Export Citation
  • 82

    GrayRJPockajBAKirkwoodJM. An update on adjuvant interferon for melanoma. Cancer Control2002;9:1621.

  • 83

    HauschildAGogasHTarhiniA. Practical guidelines for the management of interferon-alpha-2b side effects in patients receiving adjuvant treatment for melanoma: expert opinion. Cancer2008;112:982994.

    • Search Google Scholar
    • Export Citation
  • 84

    HurleyKEChapmanPB. Helping melanoma patients decide whether to choose adjuvant high-dose interferon-alpha2b. Oncologist2005;10:739742.

    • Search Google Scholar
    • Export Citation
  • 85

    BonnenMDBalloMTMyersJN. Elective radiotherapy provides regional control for patients with cutaneous melanoma of the head and neck. Cancer2004;100:383389.

    • Search Google Scholar
    • Export Citation
  • 86

    StromEARossMI. Adjuvant radiation therapy after axillary lymphadenectomy for metastatic melanoma: toxicity and local control. Ann Surg Oncol1995;2:445449.

    • Search Google Scholar
    • Export Citation
  • 87

    AtallahEFlahertyL. Treatment of metastatic malignant melanoma. Curr Treat Options Oncol2005;6:185193.

  • 88

    EigentlerTKCaroliUMRadnyPGarbeC. Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials. Lancet Oncol2003;4:748759.

    • Search Google Scholar
    • Export Citation
  • 89

    HoughtonANCoitDGDaudA. NCCN Clinical Practice Guidelines in Oncology: Melanoma. J Natl Compr Canc Netw2006;4:666684.

  • 90

    SerroneLZeuliMSegaFMCognettiF. Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview. J Exp Clin Cancer Res2000;19:2134.

    • Search Google Scholar
    • Export Citation
  • 91

    MiddletonMRGrobJJAaronsonN. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol2000;18:158166.

    • Search Google Scholar
    • Export Citation
  • 92

    LeghaSSRingSPapadopoulosN. A prospective evaluation of a triple-drug regimen containing cisplatin, vinblastine, and dacarbazine (CVD) for metastatic melanoma. Cancer1989;64:20242029.

    • Search Google Scholar
    • Export Citation
  • 93

    McClayEFMastrangeloMJBelletREBerdD. Combination chemotherapy and hormonal therapy in the treatment of malignant melanoma. Cancer Treat Rep1987;71:465469.

    • Search Google Scholar
    • Export Citation
  • 94

    ChapmanPBEinhornLHMeyersML. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol1999;17:27452751.

    • Search Google Scholar
    • Export Citation
  • 95

    AgarwalaSSKeilholzUHoggD. Randomized phase III study of paclitaxel plus carboplatin with or without sorafenib as second-line treatment in patients with advanced melanoma [abstract]. J Clin Oncol2007;25(Supp 1):Abstract 8510.

    • Search Google Scholar
    • Export Citation
  • 96

    RaoRDHoltanSGIngleJN. Combination of paclitaxel and carboplatin as second-line therapy for patients with metastatic melanoma. Cancer2006;106:375382.

    • Search Google Scholar
    • Export Citation
  • 97

    AtkinsMBLotzeMTDutcherJP. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol1999;17:21052116.

    • Search Google Scholar
    • Export Citation
  • 98

    SmithFODowneySGKlapperJA. Treatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccines. Clin Cancer Res2008;14:56105618.

    • Search Google Scholar
    • Export Citation
  • 99

    LeghaSSRingSBedikianA. Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-alpha. Ann Oncol1996;7:827835.

    • Search Google Scholar
    • Export Citation
  • 100

    LeghaSSRingSEtonO. Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma. J Clin Oncol1998;16:17521759.

    • Search Google Scholar
    • Export Citation
  • 101

    EtonOLeghaSSBedikianAY. Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial. J Clin Oncol2002;20:20452052.

    • Search Google Scholar
    • Export Citation
  • 102

    AtkinsMBHsuJLeeS. Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic, malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol2008;26:57485754.

    • Search Google Scholar
    • Export Citation
  • 103

    BajettaEDel VecchioMNovaP. Multicenter phase III randomized trial of polychemotherapy (CVD regimen) versus the same chemotherapy (CT) plus subcutaneous interleukin-2 and interferon-alpha2b in metastatic melanoma. Ann Oncol2006;17:571577.

    • Search Google Scholar
    • Export Citation
  • 104

    KeilholzUPuntCJGoreM. Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group. J Clin Oncol2005;23:67476755.

    • Search Google Scholar
    • Export Citation
  • 105

    RidolfiRChiarion-SileniVGuidaM. Cisplatin, dacarbazine with or without subcutaneous interleukin-2, and interferon alpha-2b in advanced melanoma outpatients: results from an Italian multicenter phase III randomized clinical trial. J Clin Oncol2002;20:16001607.

    • Search Google Scholar
    • Export Citation
  • 106

    IvesNJStoweRLLoriganPWheatleyK. Chemotherapy compared with biochemotherapy for the treatment of metastatic melanoma: a meta-analysis of 18 trials involving 2,621 patients. J Clin Oncol2007;25:54265434.

    • Search Google Scholar
    • Export Citation
  • 107

    YaoKAHsuehECEssnerR. Is sentinel lymph node mapping indicated for isolated local and in-transit recurrent melanoma?Ann Surg2003;238:743747.

    • Search Google Scholar
    • Export Citation
  • 108

    TanJKHoVC. Pooled analysis of the efficacy of bacille Calmette-Guerin (BCG) immunotherapy in malignant melanoma. J Dermatol Surg Oncol1993;19:985990.

    • Search Google Scholar
    • Export Citation
  • 109

    WolfIHRichtigEKoperaDKerlH. Locoregional cutaneous metastases of malignant melanoma and their management. Dermatol Surg2004;30:244247.

    • Search Google Scholar
    • Export Citation
  • 110

    ThompsonJFKamPC. Isolated limb infusion for melanoma: a simple but effective alternative to isolated limb perfusion. J Surg Oncol2004;88:13.

    • Search Google Scholar
    • Export Citation
  • 111

    FrakerDLCoitDG. Isolated perfusion of extremity tumors. Regional therapy of advanced cancer. 1997:333350.

  • 112

    LensMBDawesM. Isolated limb perfusion with melphalan in the treatment of malignant melanoma of the extremities: a systematic review of randomised controlled trials. Lancet Oncol2003;4:359364.

    • Search Google Scholar
    • Export Citation
  • 113

    LindnerPDoubrovskyAKamPCThompsonJF. Prognostic factors after isolated limb infusion with cytotoxic agents for melanoma. Ann Surg Oncol2002;9:127136.

    • Search Google Scholar
    • Export Citation
  • 114

    AllenPJCoitDG. The surgical management of metastatic melanoma. Ann Surg Oncol2002;9:762770.

  • 115

    FerroneCRBen PoratLPanageasKS. Clinicopathological features of and risk factors for multiple primary melanomas. JAMA2005;294:16471654.

    • Search Google Scholar
    • Export Citation
  • 116

    CrowleyNJSeiglerHF. Late recurrence of malignant melanoma. Analysis of 168 patients. Ann Surg1990;212:173177.

  • 117

    FawzyFIFawzyNWHyunCS. Malignant melanoma. Effects of an early structured psychiatric intervention, coping, and affective state on recurrence and survival 6 years later. Arch Gen Psychiatry1993;50:681689.

    • Search Google Scholar
    • Export Citation
  • 118

    GutmanMCnaanAInbarM. Are malignant melanoma patients at higher risk for a second cancer?Cancer1991;68:660665.

  • 119

    KangSBarnhillRLMihmMCJrSoberAJ. Multiple primary cutaneous melanomas. Cancer1992;70:19111916.

  • 120

    RhodesAR. Public education and cancer of the skin. What do people need to know about melanoma and nonmelanoma skin cancer?Cancer1995;75:613636.

    • Search Google Scholar
    • Export Citation
  • 121

    BasseresNGrobJJRichardMA. Cost-effectiveness of surveillance of stage I melanoma. A retrospective appraisal based on a 10-year experience in a dermatology department in France. Dermatology1995;191:199203.

    • Search Google Scholar
    • Export Citation
  • 122

    WeissMLoprinziCLCreaganET. Utility of follow-up tests for detecting recurrent disease in patients with malignant melanomas. JAMA1995;274:17031705.

    • Search Google Scholar
    • Export Citation
  • 123

    BrennerDJHallEJ. Computed tomography--an increasing source of radiation exposure. N Engl J Med2007;357:22772284.

Article Information

Cited By

PubMed

Google Scholar

Related Articles

Metrics

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 90 90 9
PDF Downloads 36 36 5
EPUB Downloads 0 0 0